Drug Profile
Research programme: glucose transporter type 9 inhibitors - IOmet Pharma
Alternative Names: GLUT-9 inhibitors - IOmet PharmaLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator IOmet Pharma
- Class
- Mechanism of Action SLC2A9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gout
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for research development in Gout in United Kingdom
- 11 Jan 2016 IOmet Pharma has been acquired by Merck & Co
- 10 Feb 2015 Early research in Gout in United Kingdom (unspecified route)